Journey Clinical, a New York-based firm centered on offering psychedelic therapies, raised $8.5M in Collection A funding.
The spherical, which brings Journey Medical’s whole funding to ~$12M, was led by Union Sq. Ventures with participation from AlleyCorp, Fifty Years, In a position Companions, Gaingels, Palo Santo, PsyMed Ventures, Coalition Operators, Mystic Ventures, Colibri, Satori Capital, and different angel traders.
The corporate intends to make use of the funds to proceed to scale its choices throughout the US.
Co-founded by Jonathan Sabbagh (CEO) and Myriam Barthes (COO), Journey Medical gives each licensed psychotherapists and sufferers with entry to psychedelic therapies. Licensed psychotherapists obtain all the pieces they should confidently ship PAP inside their very own follow, whereas eligible sufferers acquire entry to its medical group for analysis and care, and community of licensed psychological well being professionals. The corporate began with Ketamine-Assisted Psychotherapy (KAP) and can increase to different psychotherapeutic therapies sooner or later as they proceed to be validated, researched, and accredited for broad use by the FDA.
Because the firm opened the platform in February 2022, they’ve grown from 30 to ~700 KAP psychotherapists, and have handled over 1,000 sufferers throughout the nation.